MAML2 and ovarian cancer: To characterize the YM fusion junction in ES-2 ovarian cancer cells, we amplified the YM transcript from total RNAs extracted from ES-2 cells using forward primers targeting YAP1 exons 3, 4, and 5, along with a reverse primer for MAML2 exon 2 (Figure 1A).